Grown Rogue International (GRUSF) Change in Working Capital (2012 - 2025)
Grown Rogue International's (GRUSF) quarterly Change in Working Capital came in at -$2131.2 billion in Q3 2025, down 326.9% year-on-year from $939.2 billion in Q3 2024, and down 312577055.81% quarter-over-quarter from $681808.0 in Q2 2025.
Grown Rogue International (GRUSF) Change in Working Capital (2012 - 2025) Analysis & Trends
Grown Rogue International's Change in Working Capital history runs 13 years deep, the most recent figure standing at -$2131.2 billion for Q3 2025.
- On a quarterly basis, Change in Working Capital fell 326.9% year-over-year to -$2131.2 billion in Q3 2025; TTM through Sep 2025 was -$3070.4 billion, a 426.9% decrease from a year earlier, with the FY2024 full-year figure at $1.4 million, up 371.64% from the prior year.
- Change in Working Capital eased to -$2131.2 billion in Q3 2025 per GRUSF's latest filing, from $681808.0 in the prior quarter.
- Across five years, Change in Working Capital topped out at $939.2 billion in Q3 2024 and bottomed at -$2131.2 billion in Q3 2025.
- The 5-year median for Change in Working Capital is -$404466.5 (2022), against an average of -$133.2 billion.
- Across the five-year window, Change in Working Capital retreated 7.61% in 2023 and plunged 371.19% in 2025, its largest moves.
- Year by year, Change in Working Capital stood at -$286562.0 in 2021, then sank by 35.97% to -$389648.0 in 2022, then jumped by 33.82% to -$257878.0 in 2023, then tumbled by 364218874.05% to -$939.2 billion in 2024, then plunged by 126.9% to -$2131.2 billion in 2025.
- Per Business Quant, the three latest GRUSF Change in Working Capital figures stand at -$2131.2 billion (Q3 2025), $681808.0 (Q2 2025), and -$2.0 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -617.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2,131.17 Bn |
| Sep 30, 2025 | -2,131.17 Bn |
| Jun 30, 2025 | 681,808.00 |
| Jun 30, 2025 | 681,808.00 |
| Mar 31, 2025 | -1.99 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -939.24 Bn |
| Dec 31, 2024 | -939.24 Bn |
| Sep 30, 2024 | 939.24 Bn |
| Sep 30, 2024 | 939.24 Bn |
| Jun 30, 2024 | 847,618.00 |
| Jun 30, 2024 | 847,618.00 |
| Mar 31, 2024 | -422,527.00 |
| Mar 31, 2024 | -422,527.00 |
| Oct 31, 2023 | -257,878.00 |
| Oct 31, 2023 | -257,878.00 |
| Jul 31, 2023 | -784,047.00 |
| Jul 31, 2023 | -784,047.00 |
| Apr 30, 2023 | -284,131.00 |
| Apr 30, 2023 | -284,131.00 |